Emadine 0.05% w/v, Eye drops, Solution (2011)
Βιβλιογραφική αναφορά
Στοιχεία εκδότη
| Εκδότης | Alcon Laboratories (U.K) Limited |
|---|---|
| Διεύθυνση | Pentagon Park, Boundary Way, Hemel Hempstead, Hertfordshire, HP2 7UD |
Για την προβολή της πλήρους καταχώρησης απαιτείται συνδρομή σε ισχύ.
Αποκτήστε πρόσβαση σε όλες τις πληροφορίες και τα εργαλεία του Galinos.gr δωρεάν για έναν μήνα απλά κάνοντας εγγραφή.
Δωρεάν εγγραφή
Αποκτήστε πρόσβαση σε όλες τις πληροφορίες και τα εργαλεία του Galinos.gr δωρεάν για έναν μήνα απλά κάνοντας εγγραφή.
Δωρεάν εγγραφή
Name of the medicinal product
EMADINE 0.5 mg/ml, Eye Drops, solution.
Qualitative and quantitative composition
1 ml of solution contains emedastine 0.5 mg (as difumarate) Excipients: Benzalkonium chloride 0.1 mg/ml For a full list of excipients, see section 6.1
Pharmaceutical form
Eye drops, (solution). Clear, colourless solution.
Therapeutic indications
Symptomatic treatment of seasonal allergic conjunctivitis.
Posology and method of administration
EMADINE has not been studied in clinical trials beyond six weeks. Posology The dose is one drop of EMADINE to be applied to the affected eye(s) twice daily. When used with other ophthalmic medicines, an ...
Contraindications
Hypersensitivity to emedastine or to any of the excipients.
Special warnings and precautions for use
Ocular corneal infiltrates Ocular corneal infiltrates were reported in conjunction with the use of EMADINE. In case of corneal infiltrates, the product should be discontinued and appropriate management ...
Interaction with other medicinal products and other forms of interaction
No interaction studies have been performed.
Pregnancy and lactation
Pregnancy There are no adequate data from the use of emedastine in pregnant women. Studies in animals have shown reproductive toxicity (see section 5.3). The potential risk for humans is unknown. Nevertheless, ...
Effects on ability to drive and use machines
As with any ocular medication, if transient blurred vision occurs at instillation, the patient should wait until the vision clears before driving or using machinery.
Undesirable effects
In 13 clinical studies involving 696 patients, Emadine was administered one to four times daily in both eyes for up to 42 days. In clinical trials, approximately 7% of patients experienced an adverse drug ...
Overdose
No data are available in humans regarding overdose by accidental or deliberate ingestion. In case of accidental ingestion of the content of a bottle of EMADINE, the potential of emedastine to increase ...
Pharmacodynamic properties
Pharmacotherapeutic group: decongestants and antiallergics; other antiallergics ATC code: S01GX06 Emedastine is a potent selective and topically effective histamine H<sub>1</sub> antagonist (K<sub>i</sub> ...
Pharmacokinetic properties
Absorption Emedastine is absorbed systemically, as are other topically administered drug substances. In a study involving ten normal volunteers dosed bilaterally twice daily for 15 days with EMADINE 0.5 ...
Preclinical safety data
Emedastine difumarate demonstrated low acute toxicity in a number of species by various routes of administration. No clinically significant local or systemic effects were observed in long-term topical ...
List of excipients
Benzalkonium chloride 0.1 mg/ml Trometamol Sodium chloride Hypromellose Hydrochloric acid/sodium hydroxide (to adjust pH) Purified water
Incompatibilities
Not applicable.
Shelf life
30 months. EMADINE should not be used for longer than 4 weeks after first opening.
Special precautions for storage
Do not store above 25°C.
Nature and contents of container
EMADINE is supplied in 5 ml and 10 ml opaque plastic DROP-TAINER bottles. Not all pack sizes may be marketed.
Special precautions for disposal and other handling
No special requirements.
Marketing authorization holder
Alcon Laboratories (UK) Ltd Pentagon Park Boundary Way Hemel Hempstead Herts HP2 7UD United Kingdom
Marketing authorization number(s)
EU/1/98/095/001-2
Date of first authorization / renewal of the authorization
Date of first authorisation: 27th January 1999 Date of last renewal: 29th January 2004
Date of revision of the text
30 November 2010